生物制剂治疗前常规胸部X线检查在CRSwNP中的有限价值
Limited value of routine chest X-rays before biologic therapy in CRSwNP.
文献信息
| PMID | 42757602 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Kumanan Rune Nanthan |
| 作者单位 | Department of Otorhinolaryngology, Head and Neck Surgery, Aalborg University Hospital. |
| 期刊 | Danish medical journal |
| SCI 分区 | Q3 |
| IF | 1.3 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 鼻科 |
中文摘要
引言： 自2022年起，丹麦已批准生物制剂用于治疗慢性鼻窦炎伴鼻息肉（CRSwNP）。全球气道指导小组将胸部X线（CXR）作为治疗前筛查手段，以识别肺部疾病并监测不良反应。本研究评估了在CRSwNP患者开始生物治疗前常规CXR筛查的效用。
方法： 基线数据，包括胸部X线，在全国性全球气道注册中心（经丹麦研究伦理委员会批准，编号：H-21020685）前瞻性收集，并于2025年5月进行分析。
结果： 共识别并纳入511例患者（男性335例，女性176例；平均年龄46.5 ± 14.6岁）；其中247例患者开始接受生物制剂治疗。在治疗组中，136例（55%）CXR正常，12例（5%）有异常发现。在264例未接受生物制剂治疗的患者中，143例（54%）CXR正常，10例（4%）显示异常发现。
结论： 在CRSwNP患者生物治疗前进行常规基线CXR筛查发现的异常结果很少。因此，常规CXR可能提供的临床获益有限。
资助： 全球气道数据库由葛兰素史克、赛诺菲和阿斯利康资助。任何制药公司均无权访问数据。
试验注册： 不相关。
英文摘要
INTRODUCTION: Biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) have been approved in Denmark since 2022. Chest X-ray (CXR) was implemented by the Global Airways Steering Group as pre-treatment screening to identify pulmonary conditions and monitor adverse effects. This study evaluates the utility of routine CXR screening before initiating biological therapy in patients with CRSwNP.
METHODS: Baseline data, including chest X-ray, were collected prospectively in the nationwide Global Airways Registry (approved by the Danish Research Ethics Committee R. no.: H-21020685) and analysed in May 2025.
RESULTS: A total of 511 patients (335 males, 176 females; mean age 46.5 ± 14.6) years were identified and included in this study; 247 patients were initiated on biologic therapy. In the treatment group, 136 (55%) had normal CXRs, and 12 (5%) had abnormal findings. Among the 264 patients who did not receive biologic treatment, 143 (54%) had normal CXRs and ten (4%) demonstrated abnormal findings.
CONCLUSIONS: Routine baseline CXR screening before biologic therapy in patients with CRSwNP identified few abnormal findings. Accordingly, routine CXR is likely to offer limited clinical benefit.
FUNDING: The Global Airways database is funded by GlaxoSmithKline, Sanofi and Astra Zeneca. None of the pharmaceutical companies has access to data.
TRIAL REGISTRATION: Not relevant.